医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating Effects of the Chronic Disease

2023年05月22日 PM06:30
このエントリーをはてなブックマークに追加


 

JIANGSU, China

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of gout to help mark Gout Awareness Day, May 22, 2023. The company released a video, https://atombp.us/ highlighting causes of the disease, how it can lead to more serious conditions and the company’s efforts to develop a new treatment.

Dr. William Shi, Founder and CEO of Atom Bioscience stated, “In treating gout, we have to do more than ease the painful symptoms of gout flare-ups. We must target the underlying cause by reducing excessive uric acid levels in the blood, which not only lead to gout, but also serious conditions such as permanent joint damage, heart attacks and kidney disease. The patient needs to bring their serum uric acid down to 5mg/dL.”

More than 55 million people suffer from gout worldwide, and its prevalence is increasing yearly. Over 9.3 million people in the U.S suffer from the disease, and the annual cost to the U.S. health care system is tens of billions of dollars.

Gout is one of the most common types of inflammatory arthritis. It is caused by a long-term condition known as hyperuricemia, defined as excessive uric acid levels in the blood (> 7 mg/dL). The build-up of uric acid is caused by genetic mutations in uric acid transport mechanisms in the kidney and bowel.

When the transporters don’t function, uric acid is not properly excreted from the body. Excessive uric acid can lead to the formation of crystals in joints and soft tissues, causing debilitating inflammation and the development of urate kidney stones.

About Atom Bioscience

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. For more information please visit: https://atombp.us/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005227/en/

CONTACT

Media:

Daniel Eramian

Opus Biotech Communications

http://opusbiotech.com/

425-306-8716

同じカテゴリーの記事 

  • Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
  • エスリのテクノロジーをALS治療開発研究所が治験場所検索に採用
  • ALS Therapy Development Institute利用Esri技术绘制临床试验地图
  • Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
  • コルマーBNH、ヘモヒムの二重機能で国際競争力を強化